Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2025 07:32 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Patent publication in Europe strengthens Clearmind’s global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine...
April 23, 2025 08:25 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

The Company is now preparing for the enrollment of the first patient to receive Clearmind’s innovative treatment as part of the trial Vancouver, Canada, April 23, 2025 (GLOBE NEWSWIRE) -- Clearmind...
April 17, 2025 07:38 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
April 16, 2025 08:40 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
March 18, 2025 07:32 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform Vancouver, Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND),...
April 17, 2024 07:49 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery...
June 01, 2022 08:11 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India

The patent was granted by India’s Office of the Controller-General of Patents, Designs and Trademarks VANCOUVER, June 01, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink:...